Disease‐Modifying Antirheumatic Drug ( DMARD ) use and associated survival After Lung Cancer in patients with Rheumatoid Arthritis

OBJECTIVES: Despite the therapeutic benefits of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA), concerns remain about their safety in patients with malignancy. Among patients with RA, we evaluated DMARD treatment patterns after lung cancer diagnosis and their association with survival. METHODS: We conducted a retrospective cohort study using the Veterans Affairs (VA) Corporate Data Warehouse (2002-2022). Among patients with RA, incident lung cancers were identified from VA Oncology data. Information on comorbidities, smoking history, cancer stage at diagnosis, and histology were collected. DMARD exposure (none, conventional synthetic DMARDs [csDMARDs] only, and biologic or targeted synthetic DMARDs [b/tsDMARDs] (with or without csDMARDs)) were assessed at landmark points, during the first 3-months and 12-months, after cancer diagnosis. Associations between DMARD class and mortality were estimated using Cox proportional hazards models adjusted with energy balancing weights to balance demographic, RA-related, comorbidity, and cancer-related covariates across exposure groups. RESULTS: Among 1,651 patients with RA and lung cancer, 1,334 survived beyond 3 months and were included in the primary landmark analysis. DMARD exposure groups included no DMARD use in 498 patients (37.3%), csDMARD use in 643 (48.2%), and b/ts/combination DMARD use in 193 (14.5%). In adjusted analyses, neither csDMARDs nor b/ts/combination DMARDs were significantly associated with all-cause mortality or lung cancer-specific mortality at 3 years. Similar associations were observed in the 12-month landmark analysis. CONCLUSIONS: In U.S. Veterans with RA and lung cancer, DMARD use during the first year following cancer diagnosis was not associated with an increased 3-year mortality.

Authors

Institutions

Publication Details

Journal
Arthritis Care & Research
Published
2026-11-20
DOI
https://doi.org/10.1002/acr.80209
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Disease‐Modifying Antirheumatic Drug ( DMARD ) use and associated survival After Lung Cancer in patients with Rheumatoid Arthritis

Jeffrey R. Curtis, Namrata Singh, Jennifer L. Barton, Aaron J. Baraff et al.
Arthritis Care & Research
Rheumatoid Arthritis Research and Therapies
article

Disease‐Modifying Antirheumatic Drug ( DMARD ) use and associated survival After Lung Cancer in patients with Rheumatoid Arthritis

Jeffrey R. Curtis, Namrata Singh, Jennifer L. Barton, Aaron J. Baraff, Chunxiao Li, Varun Nandakumar, Noel S Weiss, Nicholas Smith, Siddharth Singh, Alexander Peterson
article en

Abstract

OBJECTIVES: Despite the therapeutic benefits of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA), concerns remain about their safety in patients with malignancy. Among patients with RA, we evaluated DMARD treatment patterns after lung cancer diagnosis and their association with survival. METHODS: We conducted a retrospective cohort study using the Veterans Affairs (VA) Corporate Data Warehouse (2002-2022). Among patients with RA, incident lung cancers were identified from VA Oncology data. Information on comorbidities, smoking history, cancer stage at diagnosis, and histology were collected. DMARD exposure (none, conventional synthetic DMARDs [csDMARDs] only, and biologic or targeted synthetic DMARDs [b/tsDMARDs] (with or without csDMARDs)) were assessed at landmark points, during the first 3-months and 12-months, after cancer diagnosis. Associations between DMARD class and mortality were estimated using Cox proportional hazards models adjusted with energy balancing weights to balance demographic, RA-related, comorbidity, and cancer-related covariates across exposure groups. RESULTS: Among 1,651 patients with RA and lung cancer, 1,334 survived beyond 3 months and were included in the primary landmark analysis. DMARD exposure groups included no DMARD use in 498 patients (37.3%), csDMARD use in 643 (48.2%), and b/ts/combination DMARD use in 193 (14.5%). In adjusted analyses, neither csDMARDs nor b/ts/combination DMARDs were significantly associated with all-cause mortality or lung cancer-specific mortality at 3 years. Similar associations were observed in the 12-month landmark analysis. CONCLUSIONS: In U.S. Veterans with RA and lung cancer, DMARD use during the first year following cancer diagnosis was not associated with an increased 3-year mortality.

Arthritis Care & Research
University of Puget Sound (US), University of Washington (US), University of Utah (US), University of Alabama at Birmingham (US), VA Puget Sound Health Care System (US), Mayo Clinic Hospital (US), VA Portland Health Care System (US)
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon